Tumorigenesis and Neoplastic Progression Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels
暂无分享,去创建一个
P. Koumoutsakos | D. McDonald | A. Coxon | J. Oliner | H. Hashizume | Beverly L. Falcón | Jeyling Chou | J. Bready | D. M. McDonald | Hiroya Hashizume
[1] D. Schadendorf,et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. , 2009, Cancer research.
[2] Petros Koumoutsakos,et al. Edge detection in microscopy images using curvelets , 2009, BMC Bioinformatics.
[3] L. Ellis,et al. VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.
[4] Mark W Dewhirst,et al. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. , 2008, The Journal of surgical research.
[5] K. Ebnet. Organization of multiprotein complexes at cell–cell junctions , 2008, Histochemistry and Cell Biology.
[6] Lei Xu,et al. Perivascular nitric oxide gradients normalize tumor vasculature , 2008, Nature Medicine.
[7] Elisabetta Dejana,et al. Functionally specialized junctions between endothelial cells of lymphatic vessels , 2007, The Journal of experimental medicine.
[8] T. Mccauley,et al. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. , 2007, Cancer research.
[9] W. Shim,et al. Angiopoietin: A TIE(d) Balance in Tumor Angiogenesis , 2007, Molecular Cancer Research.
[10] D. McDonald,et al. In Vivo Actions of Angiopoietins on Quiescent and Remodeling Blood and Lymphatic Vessels in Mouse Airways and Skin , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[11] Laurent Demanet,et al. Fast Discrete Curvelet Transforms , 2006, Multiscale Model. Simul..
[12] D. Dumont,et al. Activation of Tie2 by angiopoietin-1 and angiopoietin-2 results in their release and receptor internalization , 2006, Journal of Cell Science.
[13] Takashi Urano,et al. Angiopoietins and angiopoietin-like proteins in angiogenesis. , 2006, Endothelium : journal of endothelial cell research.
[14] Ma Dong,et al. Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .
[15] Kristian Pietras,et al. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. McDonald,et al. Cellular abnormalities of blood vessels as targets in cancer. , 2005, Current opinion in genetics & development.
[17] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[18] Y. M. Lee,et al. Hypoxia-responsive element-mediated soluble Tie2 vector exhibits an anti-angiogenic activity in vitro under hypoxic condition. , 2005, International journal of oncology.
[19] Lei Xu,et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.
[20] Thomas Hartmann,et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. , 2004, Cancer cell.
[21] Gavin Thurston,et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. , 2004, The American journal of pathology.
[22] Elisabetta Dejana,et al. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. , 2004, Physiological reviews.
[23] Elisabetta Dejana,et al. Endothelial cell–cell junctions: happy together , 2004, Nature Reviews Molecular Cell Biology.
[24] A. Carè,et al. Angiopoietin decoy secreted at tumor site impairs tumor growth and metastases by inducing local inflammation and altering neoangiogenesis , 2004, Cancer Immunology, Immunotherapy.
[25] 衛藤 剛. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma : possible in vivo regulation via induction of proteases , 2004 .
[26] L. Ellis,et al. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. , 2003, Cancer research.
[27] P. Newman,et al. Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology. , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[28] H. Augustin,et al. Angiopoietin-1 and Angiopoietin-2 Share the Same Binding Domains in the Tie-2 Receptor Involving the First Ig-like Loop and the Epidermal Growth Factor-like Repeats* , 2003, The Journal of Biological Chemistry.
[29] M. Teh,et al. Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. , 2002, Experimental cell research.
[30] P. Campochiaro,et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. , 2002, Developmental cell.
[31] Richard A. Lang,et al. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[32] Rakesh K Jain,et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.
[33] M. Teh,et al. Inhibition of angiopoietin‐1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice , 2001, International journal of cancer.
[34] K. Alitalo,et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. , 2001, Cardiovascular research.
[35] L. Ellis,et al. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. , 2001, Cancer research.
[36] I. Stamenkovic,et al. Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. , 2001, The American journal of pathology.
[37] H. Augustin,et al. Blood vessel maturation in a 3‐dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[38] S. McLeskey,et al. Expression and function of angiopoietin-1 in breast cancer , 2000, British Journal of Cancer.
[39] Ji-Hye Kim,et al. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway , 2000, Oncogene.
[40] G. Yancopoulos,et al. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF , 1999, Oncogene.
[41] M. Corada,et al. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[42] M. Dewhirst,et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie 2 ( cancer y adenovirus y soluble receptor y tumor angiogenesis ) , 1998 .
[43] M. Dewhirst,et al. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. , 1997, The Journal of clinical investigation.
[44] Thomas N. Sato,et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.
[45] Pamela F. Jones,et al. Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.
[46] Pamela F. Jones,et al. Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.